Accedi

Bibliografie tematiche / Pulmonary surfactant

Indice

Articoli di riviste
Tesi
Libri
Capitoli di libri
Atti di convegni
Rapporti di organizzazioni

Letteratura scientifica selezionata sul tema "Pulmonary surfactant"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 9 giugno 2025

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Pulmonary surfactant".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "Pulmonary surfactant"

1

van Golde, LMG, JJ Batenburg, and B. Robertson. "The Pulmonary Surfactant System." Physiology 9, no. 1 (February 1, 1994): 13–20. http://dx.doi.org/10.1152/physiologyonline.1994.9.1.13.

Testo completo

Abstract (sommario):

The pulmonary surfactant system includes specific proteins involved in the regulation of surfactant secretion and recycling, conversion of secreted lamellar bodies to tubular myelin, film adsorption, and stimulation of alveolar macrophages. Hydrophobic proteins are essential for the rapid physiological action of exogenous surfactants currently used in clinical practice.

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Ramanathan, Rangasamy. "Surfactants in the Management of Respiratory Distress Syndrome in Extremely Premature Infants." Journal of Pediatric Pharmacology and Therapeutics 11, no. 3 (July 1, 2006): 132–44. http://dx.doi.org/10.5863/1551-6776-11.3.132.

Testo completo

Abstract (sommario):

Respiratory distress syndrome (RDS) is primarily due to decreased production of pulmonary surfactant, and it is associated with significant neonatal morbidity and mortality. Exogenous pulmonary surfactant therapy is currently the treatment of choice for RDS, as it demonstrates the best clinical and economic outcomes. Studies confirm the benefits of surfactant therapy to include reductions in mortality, pneumothorax, and pulmonary interstitial emphysema, as well as improvements in oxygenation and an increased rate of survival without bronchopulmonary dysplasia. Phospholipids (PL) and surfactant-associated proteins (SP) play key roles in the physiological activity of surfactant. Different types of natural and synthetic surfactant preparations are currently available. To date, natural surfactants demonstrate superior outcomes compared to the synthetic surfactants, at least during the acute phase of RDS. This disparity is often attributed to biochemical differences including the presence of surfactant-associated proteins in natural products that are not found in the currently available synthetic surfactants. Comparative trials of the natural surfactants strive to establish the precise differences in clinical outcomes among the different preparations. As new surfactants become available, it is important to evaluate them relative to the known benefits of the previously existing surfactants. In order to elucidate the role of surfactant therapy in the management of RDS, it is important to review surfactant biochemistry, pharmacology, and outcomes from randomized clinical trials.

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Satyam Prakash, Hem Shankar Yadav, and Om Prakash Yadav. "Pulmonary Surfactant in Health and Disease: An Overview." Janaki Medical College Journal of Medical Science 12, no. 03 (December 31, 2024): 108–22. https://doi.org/10.3126/jmcjms.v12i03.73990.

Testo completo

Abstract (sommario):

Surfactant is a complex mixture of phospholipids, mainly dipalmitoylphosphatidylcholine (DPCC) and surfactant proteins (SP); SP-A, SP-B, SP-C, and SP-D. DPCC plays a crucial role in lowering the surface tension, while SPs provide immunity against invading pathogens. SPs also enhance the activity of phospholipids, aiding in the adsorption and spread of surfactants all over the alveolar surface. Surfactant production starts as early as 24 weeks of gestation in humans and peaks at about 36-38 weeks. The generation and secretion of lung surfactants are tightly regulated processes. Surfactant is synthesized by type II alveolar cells and stored in lamellar bodies. Following stimulation, these lamellar bodies combine with the cell membrane and release their content into the alveolar spaces. Respiratory distress syndrome (RDS) is a fatal disease that primarily occurs in premature infants, and is mainly caused by the absence or dysfunction of pulmonary surfactant. The alveoli collapse due to surfactant insufficiency impairs the gas exchange in RDS causing respiratory failure. One of the treatment options for RDS in preterm infants is surfactant replacement therapy (SRT), where exogenous surfactant preparations are given to replete the levels of surfactant in the lungs. Prophylactic corticosteroids given at about 24 to 34 weeks of gestation to the pregnant mother may prevent surfactant deficiency in babies as it hastens surfactant production. In this review, we have explored the role of surfactants in the normal functioning of the lungs and different disease conditions.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Dipak, Kumar Dhar, and Paul Debasish. "Surfactant Replacement Therapy: An Overview." International Journal of Science and Healthcare Research 5, no. 2 (June 30, 2020): 399–406. https://doi.org/10.5281/zenodo.3931623.

Testo completo

Abstract (sommario):

Pulmonary surfactant is a soap-like chemical synthesized by type II alveolar pneumocytes and is a mixture of phospholipids (predominantly dipalmitoylphosphatidylcholine), some other lipids and proteins. Its main functions include lowering the surface tension and maintaining the stability of alveoli. The first documented trial involving exogenous use of surfactants as a therapy was recorded in early 1970s using synthetically produced phospholipid mixtures once the chemical composition of surfactants was deciphered. Gradually there was a transition to the use of more natural sources. And animal derived surfactants like Surfactant TA, Beractant, Bovactant, Poractant Alfa etc. were then introduced. Recent works have highlighted the physiological importance of the surfactant-proteins and present day exogenous surfactants are mostly synthetic combinations incorporating the protein-part, either the whole surfactant proteins or peptides that act like surfactant proteins. Examples of this group include lucinactant, rSP-C surfactant, CHF 5633 etc. The commonest therapeutic indication of surfactants is in preterm infants suffering from Infant Respiratory Distress Syndrome (IRDS) or Hyaline Membrane Disease. Present guidelines recommend the use of early rescue therapy rather than prophylactic use of surfactant as it reduces acute pulmonary injury and the need for mechanical ventilation. Multiple-dose regimen has been found to be more effective than single dose surfactant therapy and minimum 100 mg/kg of surfactant is recommended. LISA is preferred method of delivering surfactant when baby is breathing spontaneously, on nasal CPAP or when intubation is not required for treatment. Exogenous surfactants form the mainstay of therapy in these infants born with deficiency of pulmonary surfactants which predisposes their lungs to collapse.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Bernhard, Wolfgang, Andreas Gebert, Gertrud Vieten, Gunnar A. Rau, Jens M. Hohlfeld, Anthony D. Postle, and Joachim Freihorst. "Pulmonary surfactant in birds: coping with surface tension in a tubular lung." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 281, no. 1 (July 1, 2001): R327—R337. http://dx.doi.org/10.1152/ajpregu.2001.281.1.r327.

Testo completo

Abstract (sommario):

As birds have tubular lungs that do not contain alveoli, avian surfactant predominantly functions to maintain airflow in tubes rather than to prevent alveolar collapse. Consequently, we have evaluated structural, biochemical, and functional parameters of avian surfactant as a model for airway surfactant in the mammalian lung. Surfactant was isolated from duck, chicken, and pig lung lavage fluid by differential centrifugation. Electron microscopy revealed a uniform surfactant layer within the air capillaries of the bird lungs, and there was no tubular myelin in purified avian surfactants. Phosphatidylcholine molecular species of the various surfactants were measured by HPLC. Compared with pig surfactant, both bird surfactants were enriched in dipalmitoylphosphatidylcholine, the principle surface tension-lowering agent in surfactant, and depleted in palmitoylmyristoylphosphatidylcholine, the other disaturated phosphatidylcholine of mammalian surfactant. Surfactant protein (SP)-A was determined by immunoblot analysis, and SP-B and SP-C were determined by gel-filtration HPLC. Neither SP-A nor SP-C was detectable in either bird surfactant, but both preparations of surfactant contained SP-B. Surface tension function was determined using both the pulsating bubble surfactometer (PBS) and capillary surfactometer (CS). Under dynamic cycling conditions, where pig surfactant readily reached minimal surface tension values below 5 mN/m, neither avian surfactant reached values below 15 mN/m within 10 pulsations. However, maximal surface tension of avian surfactant was lower than that of porcine surfactant, and all surfactants were equally efficient in the CS. We conclude that a surfactant composed primarily of dipalmitoylphosphatidylcholine and SP-B is adequate to maintain patency of the air capillaries of the bird lung.

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Ignatova, G. L., V. N. Antonov, and I. A. Zakharova. "The use of exogenous surfactant in pulmonological practice." Meditsinskiy sovet = Medical Council, no. 5 (May 9, 2024): 41–48. http://dx.doi.org/10.21518/ms2024-089.

Testo completo

Abstract (sommario):

A lung surfactant is a complex mixture of lipids and proteins necessary to maintain proper lung function. Drug changes play an important role in chronic lung diseases such as chronic obstructive pulmonary disease, bronchial asthma and idiopathic pulmonary fibrosis. The purpose of this article is to substantiate the use of exogenous surfactant in various respiratory diseases, based on the analysis of publications in domestic and international medical journals, as well as their own experience of application in real clinical practice. This review primarily discusses the contribution of pulmonary surfactants to maintaining homeostasis of the respiratory system; optimal delivery routes; differences between natural and synthetic surfactant; diseases associated with impaired surfactant production, such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, acute respiratory distress syndrome, pulmonary alveolar proteinosis, cystic fibrosis. Special attention is paid to the immunological properties of specific proteins of surfactants A and D, their effect on protection against respiratory viral infection. Data on the direct effect of exogenous surfactant on pulmonary function, an increase in post-bronchodilation FEV1 and FVC are presented. Special attention is paid to the use of surfactant in the new coronavirus infection COVID-19. Pharmacological and therapeutic strategies to improve pulmonary surfactant dysfunction can prevent alveolar collapse, reduce the proinflammatory response, and limit viral infection. Currently, the use of surfactant preparations for the treatment of various respiratory diseases is being studied in several clinical trials, which will significantly revise the understanding of the therapeutic possibilities of an exogenous surfactant and expand its application areas.

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Suresh, G. K., and R. F. Soll. "Exogenous Surfactant Therapy in Newborn Infants." Annals of the Academy of Medicine, Singapore 32, no. 3 (May 15, 2003): 335–45. http://dx.doi.org/10.47102/annals-acadmedsg.v32n3p335.

Testo completo

Abstract (sommario):

Exogenous surfactant therapy has an established role in the management of neonatal respiratory distress syndrome (RDS). This article summarises the current evidence on surfactant therapy. The use of surfactant for the treatment or prophylaxis of neonatal RDS results in a 30% to 65% relative reduction in the risk of pneumothorax and up to a 40% relative reduction in the risk of mortality. Adverse effects, of which pulmonary haemorrhage is of most concern, are infrequent and long-term follow-up studies of treated patients are reassuring. Natural surfactants have advantages over synthetic surfactants, including a lower frequency of pneumothorax and a lower mortality. Prophylactic administration of surfactant is preferred over ‘rescue’ administration, especially in infants of <30 weeks’ gestation, as it decreases the risk of pneumothorax, pulmonary interstitial emphysema and neonatal mortality. Prophylaxis can be administered after initial resuscitation and stabilisation. In preterm infants who do not receive prophylactic surfactant, the first dose of surfactant should be administered as early as possible – early selective treatment decreases the risk of pneumothorax, pulmonary interstitial emphysema, chronic lung disease and neonatal mortality. A regimen of using multiple doses of surfactant if required has advantages over a single dose regimen. Exogenous surfactant therapy has also been used in neonatal respiratory disorders other than RDS. In trials in severe meconium aspiration syndrome, surfactant therapy reduced the need for extracorporeal membrane oxygenation. Its role in other disorders requires testing. The development and testing of newer surfactants is in progress.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

PUTMAN, Esther, Lambert A. J. M. CREUWELS, Lambert M. G. van GOLDE, and Henk P. HAAGSMAN. "Surface properties, morphology and protein composition of pulmonary surfactant subtypes." Biochemical Journal 320, no. 2 (December 1, 1996): 599–605. http://dx.doi.org/10.1042/bj3200599.

Testo completo

Abstract (sommario):

Separation of surfactant subtypes is now commonly used as a parameter in assessing the amount of active compared with inactive material in various models of lung injury. The protein content, morphology and surface activity were determined of the heavy and light subtype isolated by differential centrifugation. Here we report the presence of surfactant proteins B and C in the heavy subtype but not in the light subtype. Adsorption studies revealed that separation of fast adsorbing bronchoalveolar lavage resulted in slowly adsorbing heavy and light subtypes. Surfactant, reconstituted from heavy and light fractions, did not show a high adsorption rate. It is concluded that the isolation procedures might result in a loss of fast adsorbing surfactant structures. Surface area cycling was used as a model in vitro for the extracellular surfactant metabolism. The heavy subtype is converted into the light subtype during conversion. Conversion performed with resuspended heavy subtype revealed the generation of a disparate subtype. Furthermore it was found that the conversion was dependent on preparation and handling of the samples before cycling. Finally, adsorption studies at low surfactant concentrations revealed a delayed adsorption of lipid-extracted surfactants compared with natural surfactants. These observations emphasize the importance of the (surfactant-associated protein A-dependent) structural organization of surfactant lipids in the adsorption process.

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Dushianthan, Ahilanandan, Michael P. W. Grocott, Ganapathy Senthil Murugan, Tom M. A. Wilkinson, and Anthony D. Postle. "Pulmonary Surfactant in Adult ARDS: Current Perspectives and Future Directions." Diagnostics 13, no. 18 (September 15, 2023): 2964. http://dx.doi.org/10.3390/diagnostics13182964.

Testo completo

Abstract (sommario):

Acute respiratory distress syndrome (ARDS) is a major cause of hypoxemic respiratory failure in adults, leading to the requirement for mechanical ventilation and poorer outcomes. Dysregulated surfactant metabolism and function are characteristic of ARDS. A combination of alveolar epithelial damage leading to altered surfactant synthesis, secretion, and breakdown with increased functional inhibition from overt alveolar inflammation contributes to the clinical features of poor alveolar compliance and alveolar collapse. Quantitative and qualitative alterations in the bronchoalveolar lavage and tracheal aspirate surfactant composition contribute to ARDS pathogenesis. Compared to neonatal respiratory distress syndrome (nRDS), replacement studies of exogenous surfactants in adult ARDS suggest no survival benefit. However, these studies are limited by disease heterogeneity, variations in surfactant preparations, doses, and delivery methods. More importantly, the lack of mechanistic understanding of the exact reasons for dysregulated surfactant remains a significant issue. Moreover, studies suggest an extremely short half-life of replaced surfactant, implying increased catabolism. Refining surfactant preparations and delivery methods with additional co-interventions to counteract surfactant inhibition and degradation has the potential to enhance the biophysical characteristics of surfactant in vivo.

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Nguyen, Thuy N., Stephanie M. Cunsolo, Peter Gal, and J. Laurence Ransom. "Infasurf and Curosurf: Theoretical and Practical Considerations with New Surfactants." Journal of Pediatric Pharmacology and Therapeutics 8, no. 2 (April 1, 2003): 97–114. http://dx.doi.org/10.5863/1551-6776-8.2.97.

Testo completo

Abstract (sommario):

Type II pneumocytes, normally responsible for surfactant production and release, are insufficiently formed and differentiated in the premature infant born before 34 weeks' gestation. Without an adequate amount of pulmonary surfactant, alveolar surface tension increases, leading to collapse and decreased lung compliance. Pulmonary surfactants are naturally occurring substances made of lipids and proteins. They lower surface tension at the interface between the air in the lungs, specifically at the alveoli, and the blood in the capillaries. This review examines the relative benefits of the two most recently marketed surfactants, calfactan (Infasurf) and poractant alfa (Curosurf).

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Tesi sul tema "Pulmonary surfactant"

1

Lewis, R. W. "Pulmonary surfactant metabolism." Thesis, Cardiff University, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.332108.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Hockey, Peter Morey. "Pulmonary surfactant and asthma." Thesis, University of Southampton, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274434.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Nilsson, Kristina. "Solute exchange across the alveolo-capillary barrier." Lund : Depts. of Clinical Physiology, Malmö University Hospital and Lund University Hospital, Lund University, 1997. http://books.google.com/books?id=A0hrAAAAMAAJ.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Mo, Young Keun. "Surfactant proteins in extra pulmonary sites /." [St. Lucia, Qld.], 2005. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe19083.pdf.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Sullivan, Lucy Catherine. "The molecular evolution of vertebrate pulmonary surfactant /." Title page, summary and introduction only, 1996. http://web4.library.adelaide.edu.au/theses/09SB/09sbs949.pdf.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Worthman, Lynn-Ann D. "Surfactant protein A (SP-A) affects pulmonary surfactant morphology and biophysical properties." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0014/MQ34241.pdf.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Wood, Philip. "Control of pulmonary surfactant secretion : an evolutionary perspective /." Title page, table of contents and abstract only, 1999. http://web4.library.adelaide.edu.au/theses/09PH/09phw878.pdf.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Mander, Ann. "Pulmonary surfactant and neutrophil function in cystic fibrosis." Thesis, University of Southampton, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.310701.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

McCarty, Kenneth Dean. "Characterization of pulmonary surfactant apoproteins in the diabetic mouse." CSUSB ScholarWorks, 1989. https://scholarworks.lib.csusb.edu/etd-project/512.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Espinosa, Frank F. (Frank Francis). "Exogenous surfactant transport through the pulmonary airways : improving surfactant replacement therapy for neonatal respiratory distress syndrome." Thesis, Massachusetts Institute of Technology, 1996. http://hdl.handle.net/1721.1/10974.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Libri sul tema "Pulmonary surfactant"

1

Rooney, Seamus A. Lung surfactant: Cellular and molecular processing. Austin, TX: Landes Bioscience, 1998.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Kaushik, Nag, ed. Lung surfactant function and disorder. Boca Raton: Taylor & Francis, 2005.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

1952-, Müller B., Wichert P. von, and International Symposium on Lung Surfactant (4th : 1992 : Marburg, Germany), eds. Lung surfactant: Basic research in the pathogenesis of lung disorders. Basel: Karger, 1994.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

R, Bourbon Jacques, ed. Pulmonary surfactant: Biochemical, functional, regulatory, and clinical concepts. Boca Raton: CRC Press, 1991.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

1935-, Robertson Bengt, Golde, Lambert M. G. van, 1940-, and Batenburg J. J, eds. Pulmonary surfactant: From molecular biology to clinical practice. Amsterdam: Elsevier, 1992.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Laboratories, Ross, ed. Surfactant treatment of lung diseases: Report of the 96th Ross Conference on Pediatric Research. Columbus, Ohio: Ross Laboratories, 1988.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

G, Bevilacqua, Parmigiani Stefano, and Robertson Bengt 1935-, eds. Surfactant in clinical practice: Proceedings of an international symposium, Parma, June 4-5, 1990. Chur, Switzerland: Harwood Academic Publishers, 1993.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Devidas, Menon, and Canadian Coordinating Office for Health Technology Assessment., eds. Exosurf Neonatal for surfactant replacement therapy. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1991.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

International Symposium on Surfactant Replacement Therapy (1987 Rotterdam, Netherlands). Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Berlin: Springer-Verlag, 1988.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

R, Wauer R., ed. Respiratory distress syndrome of premature infants: Significance of surfactant and its pharmacological influence : pre-congress workshop of the 10th European Congress of Perinatal Medicine, Leipzig, GDR, August 12, 1986. Berlin: Volk und Gesundheit, 1987.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Capitoli di libri sul tema "Pulmonary surfactant"

1

Alemanno, Fernando. "Pulmonary Surfactant." In Biochemistry for Anesthesiologists and Intensivists, 119–21. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-26721-6_10.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Enhorning, G. "Evaluation of Pulmonary Surfactant." In Surfactant Replacement Therapy, 13–17. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73305-5_2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Harwood, John L., Llinos W. Morgan, and Tanya Greatrex. "Alveolar Surfactant." In Pulmonary Biology in Health and Disease, 44–63. New York, NY: Springer New York, 2002. http://dx.doi.org/10.1007/978-0-387-22435-0_3.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Robertson, B., and S. Schürch. "Assessment of surfactant function." In Methods in Pulmonary Research, 349–83. Basel: Birkhäuser Basel, 1998. http://dx.doi.org/10.1007/978-3-0348-8855-4_14.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Enhorning, G. "Pulmonary Surfactant: Evolution of Functional Concepts." In Surfactant Replacement Therapy, 1–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73305-5_1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Willson, Douglas F., Patricia R. Chess, Zhengdong Wang, and Robert H. Notter. "Pulmonary Surfactant: Biology and Therapy." In The Respiratory Tract in Pediatric Critical Illness and Injury, 1–14. London: Springer London, 2008. http://dx.doi.org/10.1007/978-1-84800-925-7_10.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Armbruster, S., J. Klein, E. M. Stouten, W. Erdmann, and B. Lachmann. "Surfactant in Pulmonary Oxygen Toxicity." In Oxygen Transport to Tissue IX, 345–49. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-7433-6_40.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Lachmann, B. "In Vivo Tests for Evaluation of Pulmonary Surfactant." In Surfactant Replacement Therapy, 28–36. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73305-5_4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Calkovska, Andrea, and Egbert Herting. "Exogenous Surfactant in Respiratory Distress Syndrome." In Applied Technologies in Pulmonary Medicine, 205–9. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000322778.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Pison, Ulrich, and Sylvia Pietschmann. "Host Defense Capacities of Pulmonary Surfactant." In Acute Respiratory Distress Syndrome, 87–96. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4419-8634-4_11.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "Pulmonary surfactant"

1

Gaver, Donald P., Melissa A. Krueger, and Samir N. Ghadiali. "The Influence of Surfactant Physicochemical Properties on Pulmonary Interfacial Flow Analogues." In ASME 1997 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1997. http://dx.doi.org/10.1115/imece1997-0218.

Testo completo

Abstract (sommario):

Abstract Many of the lung’s mechanical properties are influenced by pulmonary surfactant physicochemical characteristics. Pulmonary surfactant is a complex lipid-protein mixture formed in the type II alveolar cells and secreted into the alveolar subphase [1]. These substances reduce the surface tension at the air-liquid interface of the lining fluid that coats the interior of the lung. At sufficiently high concentrations, pulmonary surfactant reduces the surface tension to near zero and. in the process, stabilizes the alveoli and small airways [2–4].

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Siebert, Trina A., and Sandra Rugonyi. "Surfactant Spreading on a Thin Film Is Sensitive to Film Thickness: Implications for In Vivo Pulmonary Systems Versus In Vitro Scenarios." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-174065.

Testo completo

Abstract (sommario):

The role of pulmonary surfactant is critical to the mechanics of the lung. Pulmonary surfactant forms a monolayer film at the air-liquid interface of a thin film of fluid lining the alveoli. Without surfactant, the air-liquid surface tension would be too high and the lungs would collapse during exhalation, as is the case with premature babies who develop respiratory distress syndrome (RDS) because they lack a sufficient amount of pulmonary surfactant [1]. Because an increase in surfactant surface concentration correlates with a decrease in surface tension, the surface tension gradients resulting when a monolayer of surfactant is deposited on a thin fluid film cause the surfactant to spread. This self-spreading phenomenon is of interest for applications such as surfactant replacement therapy in infants suffering from RDS and for drug delivery [1,2].

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Kolmogorov, I. M., V. A. Timoshenko, I. V. Grigoryan, and I. M. Le-Deygen. "INTERACTION OF LIPOSOMAL FORMS OF LEVOFLOXACIN WITH PULMONARY SURFACTANT." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-77.

Testo completo

Abstract (sommario):

The interaction between liposomal levofloxacin and bovine pulmonary surfactant was investigated. It has been demonstrated using Langmuir-Wilhelmy techniques, AFM, IR and fluorescence microscopy that functionalizing the surface of liposomes with mannosylated chitosan minimizes the initial fusion of vesicles with surfactant, while also assisting in the retention of the formulation at the surfactant-air interface.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Numata-Nakamura, M., H. Lee, H. W. Chu, M. A. Seibold, and D. R. Voelker. "Pulmonary Surfactant Lipids Antagonize Human Rhinovirus Infections." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5757.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Meissner, Sven, Stefan Adami, Lilla Knels, Xiangyu Hu, Nikolaus Adams, and Edmund Koch. "Experimental And Numerical Studies On Pulmonary Surfactant." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3021.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Briva, Arturo, Leonel Malacrida, Horacio Botti, Fabiana Rocchiccioli, Juan Pablo Soto, Martin Angulo, and Ana Denicola. "Halogenated Anesthetics Impairs Biophysical Properties Of Pulmonary Surfactant." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5241.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Arciniegas Flores, R. A., I. A. Vital, K. Medepalli, D. DeMarzo, M. K. Glassberg Csete, and R. A. Alvarez. "Pulmonary Fibrosis Due to a Novel Surfactant Protein Mutation." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5437.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Suman, A., N. Sinha, H. Kaura, H. Rawal, and A. G. Espinoza. "Drowning in Surfactant - A Case of Pulmonary Alveolar Proteinosis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1478.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Hall, Stephen B., Ryan W. Loney, and Shankar B. Rananavare. "Mechanisms Of The Late Accelerated Adsorption Of Pulmonary Surfactant." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5243.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Furuhashi, K., S. Sakurai, H. Yasui, M. Karayama, Y. Suzuki, H. Hozumi, N. Enomoto, et al. "Surfactant Protein D in Patients with Chronic Pulmonary Aspergillosis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3694.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rapporti di organizzazioni sul tema "Pulmonary surfactant"

1

Cochrane, Charles G. Clinical Studies of Synthetic Peptide-Containing Pulmonary Surfactant in Patients with Adult Respiratory Distress Syndrome. Fort Belvoir, VA: Defense Technical Information Center, November 1995. http://dx.doi.org/10.21236/ada302217.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Rodríguez, Antonio Cruz, Begoña García Álvarez, and Bárbara Olmeda Lozano. El surfactante pulmonar, un sistema lipoproteico clave para la mecánica respiratoria. Sociedad Española de Bioquímica y Biología Molecular, March 2023. http://dx.doi.org/10.18567/sebbmrev_215.202303.dc004.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!